Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy

Annals of Surgery

Volumn 230, Issue 1, 1999, Pages 72-78

  Kuerer, Henry M ^a,c   Sahin, Aysegul A ^a   Hunt, Kelly K ^a   Newman, Lisa A ^a   Breslin, Tara M ^a   Ames, Fred C ^a   Ross, Merrick I ^a   Buzdar, Aman U ^b   Hortobagyi, Gabriel N ^b   Singletary, S Eva ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CLINICAL TRIAL; ERADICATION THERAPY; FEMALE; HUMAN; HUMAN TISSUE; INCIDENCE; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL DOCUMENTATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0033512788     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199907000-00011     Document Type: Article

References (32)

1. Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993; 15:3358-3366.
2. Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol 1994;12:1592-1599.
3. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 1998; 16:1298-1301.
4. Swisher SG, Holmes EC, Hunt KK, et al. The role of neoadjuvant therapy in surgically resectable esophageal cancer. Arch Surg 1996; 8:819-824.
5. Sugarbaker DJ, Herndon J, Kohman LJ, et al. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 1995; 109:473-483.
6. Delena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol 1978; 1:53-59.
7. Hortobagyi GN, Blumenschein GR, Spanos W, et al. Multimodal treatment of locoregionally advanced breast cancer. Cancer 1983; 51:763-768.
8. Lippman ME, Sorace RA, Bagley CS, et al. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. NCI Monogr 1986; 1:156-159.
9. Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994; 5:645-652.
10. Fisher B, Brown A, Mamounas E, Wieand S, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15:2483-2493.
11. Mamounas EP. Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies. Semin Oncol 1998; 25:31-35.
12. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-2685.
13. Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 1992; 69:2849-2852.
14. Schwartz GF, Birchansky CA, Komarnicky LT, et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 1994; 73:362-369.
15. Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16:93-100.
16. McCready DR, Hortobagyi GN, Kau SW, et al. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 1989; 124:21-25.
17. Botti C, Vici P, Lopez M, et al. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast. J Am Coll Surg 1995;181:202-208.
18. Kuerer HM, Newman LA, Buzdar AU, et al. Residual metastatic ALNs following neoadjuvant chemotherapy predicts disease-free survival in locally advanced breast cancer patients. Am J Surg 1998; 176:502-509.
19. American Joint Committee on Cancer. Manual for staging of cancer, 6th ed. Philadelphia: Lippincott-Raven; 1998.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 185:1457-1481.
21. Mantel N. Evaluation of survival data and two row rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170.
22. Wells CA, Heryet J, Brochier J, et al. The immunohistochemical detection of axillary micrometastases in breast cancer. Br J Cancer 1984; 50:193-197.
23. Trojani M, de Mascarel I, Bonichon F, et al. Micrometastases to ALNs from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987; 55:303-306.
24. International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult ALN micrometastases from breast cancers. Lancet 1990; 335:1565-1568.
25. Hainsworth PJ, Tjandra JJ, Stillwell RG, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993; 80:459-463.
26. Clare SE, Sener SF, Wilkens W, et al. Prognostic significance of occult lymph node metastases in node-negative breast cancer. Ann Surg Oncol 1997; 4:447-451.
27. Fisher ER, Swamidoss S, Lee CH, et al. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978; 42:2025-2031.
28. Kuerer HM, Newman LA, Fornage BD, et al. Role of ALN dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. Ann Surg Oncol 1998; 5:673-680.
29. Kuerer HM, Newman LA, Buzdar AU, et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts ALN status. Cancer J Sci Am 1998; 4:230-236.
30. Fisher B, Redmond, C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312:674-681.
31. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 222: 394-401.
32. Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet 1997; 349:1864-1867.